



REVIEW

Hidradenitis suppurativa: an update on connecting the tracts [version 1; referees: 3 approved]

Mallory K Smith¹, Cynthia L Nicholson², Angela Parks-Miller², Iltefat H Hamzavi ²

¹Wayne State University School of Medicine, Detroit, MI, USA

²Henry Ford Hospital Department of Dermatology, Detroit, MI, USA

v1 **First published:** 28 Jul 2017, 6(F1000 Faculty Rev):1272 (doi: 10.12688/f1000research.11337.1)




Latest published: 28 Jul 2017, 6(F1000 Faculty Rev):1272 (doi: 10.12688/f1000research.11337.1)

Abstract

Hidradenitis suppurativa (HS) is a devastating disease involving abscesses, sinus tracts, and inflammation classically affecting the axilla, groin, and/or anogenital region. Although the disease pathogenesis is not fully understood, recent advances suggest that HS pathology runs much deeper than the cutaneous manifestations. It is now believed that HS is a systemic inflammatory disease that gives rise to the characteristic cutaneous manifestations. This disease is problematic for both patients and physicians to manage because of a variety of diagnostic and management difficulties. This article seeks to provide updates on the current understanding of HS to increase awareness and improve management.

Open Peer Review

Referee Status: 

	Invited Referees		
	1	2	3
version 1 published 28 Jul 2017			

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Robert Micheletti**, University of Pennsylvania, USA
- 2 **Christopher Sayed**, The University of North Carolina at Chapel Hill, USA
UNC Dermatology and Skin Cancer Center, USA
- 3 **Geoffrey David Cains**, University of New South Wales, Australia

Discuss this article

Comments (0)

Corresponding author: Iltefat H Hamzavi (ihamzav1@hfhs.org)

Competing interests: Iltefat Hamzavi is the current president of the Hidradenitis Suppurativa Foundation (non-funded) and was an investigator for AbbVie. Angela Miller has served on an advisory board and as a consultant for AbbVie and is an employee of the Hidradenitis Suppurativa Foundation. Cynthia Nicholson and Mallory Smith declare that they do not have any competing interests.

How to cite this article: Smith MK, Nicholson CL, Parks-Miller A and Hamzavi IH. **Hidradenitis suppurativa: an update on connecting the tracts [version 1; referees: 3 approved]** *F1000Research* 2017, 6(F1000 Faculty Rev):1272 (doi: [10.12688/f1000research.11337.1](https://doi.org/10.12688/f1000research.11337.1))

Copyright: © 2017 Smith MK *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: The author(s) declared that no grants were involved in supporting this work.

First published: 28 Jul 2017, 6(F1000 Faculty Rev):1272 (doi: [10.12688/f1000research.11337.1](https://doi.org/10.12688/f1000research.11337.1))

Introduction

Hidradenitis suppurativa (HS) is an inflammatory disease characterized by recurrent, painful abscesses and fistulous tracts¹. Patients with HS objectively have one of the lowest quality of life measures of any dermatologic disease^{2,3}. Lesions characteristically occur in the axillary, groin, inframammary, and/or anogenital regions of the body, although other sites may be involved⁴. HS lesions may progress to form sinus tracts and expansive abscesses. Sequelae include significant pain, scarring, and psychological distress⁵. This article provides a comprehensive update on the current understanding of HS while also expanding upon the 2014 publication “Update on hidradenitis suppurativa: connecting the tracts” by Gill *et al.*¹.

Background

Epidemiology

HS was first described in 1839 by Velpeau in France¹. Since that time, and specifically throughout the past 10–20 years, much has been learned about this disease.

The average age of onset is during the early 20s, although pediatric cases are not uncommon. HS is more common in females than in males, at a rate of approximately 3:1. Additionally, HS more commonly occurs in the African-American population^{6–9}. A recent retrospective study discovered significantly elevated rates of HS in African-American patients compared to Caucasian patients (6.4% to 3.9%, respectively), although further evidence is needed to support this association⁹.

The prevalence of HS is a controversial topic, reported between 0.00033 and 4.1%, although underdiagnosis or improper diagnosis is common¹⁰. A study from 1996 by Jemec *et al.* assessed 507 individuals undergoing sexually transmitted disease screening and calculated a point prevalence of 4.1% and a 1-year prevalence of 1.0%¹¹. In 2008, Revuz *et al.* carried out two case-control studies to explore HS prevalence, which was determined to be 1%¹². In 2013, the prevalence of HS in a health insured-only population (n = 7,927) was found to be 0.053%¹³. In continuation, in 2014, a population-based study in Olmsted County, Minnesota, reviewed medical records from 1968–2008 and reported a prevalence of 0.13%. This study also indicated that the prevalence of HS is increasing, with rates of 4.3 per 100,000 between 1970 and 1979 to 9.6 per 100,000 between 2000 and 2008¹⁴. This study estimated a lower prevalence, although these findings are limited because this population’s racial and ethnic distribution was not representative of the United States. Another cross-sectional population study in Denmark evaluated HS demographics, and, overall, inverse recurrent suppuration (probable HS) prevalence was 2.1% based on a self-administered questionnaire given to adults aged 30–89¹⁵.

Overall, HS prevalence varies significantly based on study methodology; however, the disease appears to be more common than was previously considered.

Exacerbating factors

Exacerbating factors of HS include, but are not limited to, mechanical stressors such as friction from clothing, sweating, and shaving¹⁶. Of interest is the role of diet in the exacerbation or progression of disease. Owing to the possible role of hormonal

regulation in disease pathogenesis, dairy was studied, as it may elevate insulin and promote androgen stimulation through the theorized hormonal effects of casein, whey, simple sugars, and 5- α reduced dihydrotestosterone (DHT). Forty-seven patients were placed on a dairy-free diet, and 83% clinically improved, while none experienced worsening of disease, compared to the control population that did not follow the dairy-free diet¹⁷. This study reported impressive improvement; however, it failed to utilize validated assessment methods, and recall and non-response bias may have contributed to the outcome.

Brewer’s yeast is another dietary component of interest. One study followed 12 patients who eliminated foods containing brewer’s yeast, such as breads, beer, black tea, fermented cheese, and more, after the completion of HS surgery. Stabilization and eventual regression of HS throughout the one-year study period was reported¹⁸. However, because of the small sample size, future studies are needed to further elucidate the role of brewer’s yeast in HS management.

In the authors’ experience, some patients report dietary triggers, while others report that strict adherence to various diets results in no change in symptoms, suggesting that further evidence is needed to evaluate this relationship. Nonetheless, the role of diet in HS disease management is a topic of great interest in both the general and the scientific communities.

Associations and comorbidities

Obesity and cigarette smoking have known associations with HS^{12,19}. A recent retrospective questionnaire reported that the prevalence of HS in an obese population was 18.1%, significantly higher than the general population. Additionally, 35% of these subjects reported improvement in HS symptoms following bariatric surgery and subsequent weight loss⁸. Miller *et al.* observed body composition and basal metabolic rate in a cross-sectional study and determined that hospitalized HS patients had significantly higher body fat, visceral fat, BMI, waist circumference, and waist/hip ratio, while muscle and bone mass percentages were significantly lower than in controls²⁰. Additional comorbidities have been elucidated based on a case-control analysis of 2,292 HS patients, which found that arthropathies, obesity, dyslipidemia, hormonal disease such as polycystic ovarian syndrome, psychiatric disorders, drug or alcohol dependence, cardiovascular disease, and thyroid aberrancies occur more commonly in those with HS²¹.

HS is also associated with metabolic syndrome, a multifaceted disease state including diabetes mellitus/insulin resistance, hypertension, dyslipidemia, and obesity. The prevalence of metabolic syndrome in HS patients was significantly higher than in controls in a retrospective chart review, at a rate of 50.6% compared to 30.2%, respectively²². Other studies have supported this association, specifically regarding increased prevalence of obesity, hypertriglyceridemia, and insulin resistance in HS patients^{22,23}.

Metabolic disease increases the risk of cardiovascular disease, a major health concern because of the associated increases in morbidity and mortality²². Patients with HS are significantly more

likely to have atherosclerotic disease than are controls, particularly carotid artery atherosclerosis, as determined through ultrasonography. Although causation was not determined, it was theorized that systemic inflammation associated with HS promoted atherosclerosis²⁴. This finding is concerning because cardiovascular disease is often subclinical and asymptomatic, with potentially deadly consequences. It has also been hypothesized that elevated levels of the inflammatory molecules interleukin (IL)-17 and tumor necrosis factor (TNF)- α contribute to endothelial damage. This provides immunologic context to relate cardiovascular disease to HS²⁵. The risk of cardiovascular events in patients with HS was also assessed in a Danish population-based cohort study of 5,964 subjects using data collected between 1997 and 2011. Compared to controls, HS patients were at an increased risk for ischemic stroke, cardiovascular-related mechanisms of death, major adverse cardiac events, and, surprisingly, all-cause mortality²⁶. These studies provide valuable knowledge for healthcare providers in all fields of medicine, which should guide preventative screening and interventions, along with public health research.

Chronic inflammatory diseases, such as inflammatory bowel disease (IBD), are also associated with HS^{27,28}. The prevalence of IBD in 7,732 HS patients was 0.8%, significantly higher than the reported prevalence of IBD in the general population, at 0.3%. Additionally, the risk of new-onset IBD was significantly elevated in HS patients, specifically Crohn's disease (CD), with a hazard risk of 2.19, and ulcerative colitis (UC), with a hazard risk of 1.63²⁹. Another recent multicenter cross-sectional study indicated that the prevalence of IBD with HS was 3.3%; of that, 2.5% was CD and 0.8% was UC. Compared to the prevalence of IBD in the general Northern European population (0.41–0.74%), the prevalence of IBD was much higher in HS patients³⁰. Another recent population-based cohort study in Minnesota observed the rates of HS in 679 patients with IBD. The 10-year incidence of HS was 0.85%, and the 30-year incidence was 1.55%. Overall, patients with IBD were nine times more likely to develop HS compared to the general population³¹. CD exhibits many parallels with HS, as both are chronic epithelial inflammatory diseases with inhabitation of bacterial flora, have a genetic predisposition, and respond to similar medication classes²⁸.

Owing to the chronic inflammation inflicted by recurrent HS lesions, squamous cell carcinoma (SCC) is a rare but serious complication of longstanding disease, with an incidence of 0.5–4.6% over the course of the disease^{27,32}. It is hypothesized that free radical production and subsequent DNA damage provides the appropriate environment for malignant transformation, particularly in perianal regions of HS involvement^{33,34}. It is unknown if systemic inflammation from HS itself contributes to the increased risk. Of great concern, high-risk human papilloma virus (HPV) type 16 has been isolated in pathology specimens of SCC lesions in HS patients³⁵. These associations are important for healthcare providers, as HPV testing and biopsy of a suspicious lesion with subsequent early intervention is associated with improved prognosis. Risk of malignancy is also an important consideration when beginning a biologic medication, which is associated with immunosuppression.

Psychiatric diseases, specifically anxiety and depression, are associated with HS, and this is discussed in further detail in the “Psychosocial impact” section^{36,37}. Another notable association with HS is low socioeconomic status, as determined by a recent cross-sectional study by Deckers *et al.* The socioeconomic status of over 1,000 patients with HS was significantly lower than that of over 2,000 matched dermatologic controls. However, it is difficult to draw conclusions if downward drift is contributing to the socioeconomic status, as there are numerous confounding factors³⁸.

Pathophysiology

The pathophysiology of HS is not fully understood, although it is thought to be multifactorial. The disease is now believed to be a systemic inflammatory condition, contrary to previous hypotheses classifying HS as a purely cutaneous disorder.

Genetics

Both familial and sporadic cases of HS have been reported. It is thought that approximately 33% of HS cases are familial. Genetic variants of HS are heterogeneous, with several mutations identified throughout the genome, lacking a consistent genotype to phenotype correlation^{39–41}. One study of 53 Chinese patients hypothesized to have familial HS were found to have a unique phenotype consisting of an increased male prevalence, earlier onset, and more severe disease involving atypical regions such as the neck and back⁴². Because of the phenotypic variance in HS, Canoui-Poitrine *et al.* attempted to develop distinct phenotype-based subtypes of the disease, including axillary-mammary, follicular, and gluteal types. However, genetic analyses have not yet correlated with this grouping technique⁴³. Additionally, the specific phenotype “hidradenitis suppurativa fulminans” has been proposed to describe a specific, severe presentation of the disease⁴⁰. Phenotypic categorization will assist in future studies and determining a greater understanding of the varying presentations and genetics of this disease.

Some cases of HS are associated with syndromes, including pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome, related to mutations in proline-serine-threonine-phosphatase protein 1 (PSTPIP1). This gene is involved in the regulation of the inflammasome complex, a series of proteins and signaling pathways the body utilizes in response to inflammation-inducing stimuli⁴⁴. Another similar syndrome, pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH) syndrome, is also associated with PSTPIP1 gene mutations⁴⁵. Similarly, synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome has been associated with cases of HS. These relationships between HS and other auto-inflammatory diseases have bolstered the theory that HS may be auto-inflammatory in nature⁴⁶.

There is also evidence to support a relationship between familial HS and loss-of-function mutations in γ -secretase proteins, such as presenilin-1, presenilin enhancer-2, anterior pharynx defective 1, and nicastrin (NCSTN). These mutations were noted in variants of HS involving atypical regions such as the thighs and trunk^{7,47}. The protease γ -secretase plays a role in the regulation of the canonical Notch signaling pathway, which is relevant to HS because

Notch functions in the development of hair follicles, and as an immunomodulator in T-cell-mediated cellular immune responses. Inherited or acquired alterations in Notch signaling may play a pivotal role in HS disease pathogenesis⁴⁸. Cigarette smoking has been shown to decrease the activity of the Notch signaling pathway, further strengthening this association. Of note, having one of the above mutations does not guarantee disease development or progression⁴⁹.

Further, Xiao *et al.* analyzed the gene encoding NCSTN (*NCSTN*) in a human keratinocyte cell line and found that *NCSTN* knock-down cells exhibited impaired γ -secretase activity, leading to more rapid proliferation and a greater proportion of cells in the S-phase of the cell cycle. This study bolstered the theory that a deficiency in the *NCSTN* gene in familial forms of HS may play a role in abnormal keratinocyte growth and proliferation⁵⁰. Interestingly, Duchatelet *et al.* discovered a *NCSTN* mutation in a patient with PASH syndrome, interrelating genetic and auto-inflammatory hypotheses of the pathogenesis of HS⁵¹.

Finally, a retrospective study by Deckers *et al.* evaluated trends in early onset HS, defined as disease onset before age 13. A family history of HS was a significant factor in the diagnosis of early onset HS as well as more widespread disease. There were no reported differences in comorbidities in patients with early onset disease compared to controls with normal-onset HS⁵².

Etiology

Many previously accepted models of HS pathogenesis are being challenged. It is now believed that HS is a systemic inflammatory disease of multifactorial basis, possibly due to auto-inflammation⁵³.

It was formerly hypothesized that the disease originated in apocrine-bearing locations of the body, such as the groin and anogenital and axillary regions. However, the inframammary region, neck, trunk, and thighs are frequently involved as well⁷. These areas experience recurrent friction, perhaps supporting the role of mechanical stress in the development of disease. Additionally, it was previously theorized that the first step in HS disease progression was the occlusion of the follicular infundibulum due to hyperkeratosis of adjacent epithelium. This hyperkeratosis was thought to act as a nidus for secondary infection, which caused the subsequent massive local inflammation associated with classic HS lesions^{48,54}. Although follicular occlusion is paramount in the manifestations of HS, the instigating mechanism of occlusion is controversial. It has been hypothesized that these inflammatory events are instead secondary to an underlying aberrant inflammatory state in patients with HS instead of the primary cause of the disease⁵⁵.

Although the driving force behind the development of HS lesions is unknown, recent studies have proposed various theories to describe the instigating pathology. One study observed the basement membrane of lesional and clinically uninvolved skin and found abnormal epithelial support and basement membrane surrounding the follicular junction in lesional tissue based on periodic acid-Schiff (PAS) histologic staining. These findings suggested that individuals with HS may have an underlying anatomic defect

in the basement membrane predisposing to secondary infections⁵⁶. Blok *et al.* similarly evaluated perilesional biopsies in patients with HS compared to healthy controls. Contrary to the previous findings, this study found neither a significant difference in PAS staining nor a difference in many other basement membrane constituents between patients and controls. However, this study observed significant upregulation of integrins $\alpha 6$ and $\beta 4$ (signaling molecules with adhesive properties) within the sebaceous gland of HS patients compared to controls. The role of these integrins in HS is unclear at this time⁵⁷.

Additionally, it is known that keratinocytes and neutrophils play a role in the secretion of pro-inflammatory molecules in HS⁵⁸. Hotz *et al.* proposed that abnormal keratinocyte function plays a role in HS development. Compared to controls, keratinocytes in HS lesions showed a diminished inflammatory response to muramyl dipeptide, a pathogen-associated molecular pattern (PAMP) inflammatory antigen⁵⁹. Keratinocyte malfunction further suggests structural and molecular abnormalities allowing for follicular occlusion and disease progression. Although the precise cause of the follicular occlusion remains debated, cellular markers and other immunologic sources of inflammation are important topics of discussion in the ongoing search to determine the etiology of HS.

In summary, overarching themes of inflammation and abnormal cellular activity appear to provide the appropriate environment for the progression to HS clinical features. It is probable that many factors allow for altered cellular barrier mechanisms and anomalous secretion of pro-inflammatory cytokines in the progression to classic HS symptoms⁴⁸.

Inflammation in hidradenitis suppurativa

HS is a systemic inflammatory disease, and auto-inflammation is suggested to play a role in disease pathogenesis. This theory was bolstered by the association of comorbid autoimmune and inflammatory diseases, abnormal biochemical findings, and an infiltration of innate and adaptive immune cells within both lesional and perilesional skin before clinical manifestations of the disease arise⁶⁰. In particular, auto-inflammatory diseases (AIDs) are rare, hereditary, unprovoked systemic inflammatory diseases that classically occur in the absence of infection or autoantibodies. These disorders are thought to be due to altered regulation and signaling patterns in the innate immune system. As described above, HS has been associated with many AIDs^{53,61,62}.

The exact cytokine profile of HS has yet to be determined, although abnormal levels of several inflammatory cytokines have been observed in HS, with notable elevations in IL-1 β , IL-10, IL-11, IL-17A, and CXCL9 (monokine induced interferon [IFN]- γ). Additionally, mRNA and protein quantities of TNF- α , IL-1 β , and IL-10 were reportedly elevated in HS⁶³⁻⁶⁵. Interleukins are a part of the body's natural response to stressors, secreted by innate and adaptive immune cells, each with its own specific role in immunomodulation. It is important to note that individual cytokine profiles differ between patients⁶⁶. While an in-depth discussion of the abnormal cytokine profile in HS is beyond the scope of this review, notable findings and common cytokine trends associated with HS will be expanded upon.

Increased activity of the pro-inflammatory IL-23/Th17 pathway has been implicated in many chronic inflammatory diseases, recently including HS. Studies have supported that IL-12 and IL-23 were expressed in large quantities by macrophages in HS lesional skin, along with the infiltration of IL-17-producing helper-T and CD4⁺ T cells^{65,67,68}. IL-17-producing cells were similarly found in lesional and perilesional skin in HS patients. The knowledge of IL-17 as an activator of keratinocytes and source of inflammatory modulators in HS has provided important insights into the disease process as well as potential management options^{25,58,69}. These findings have important implications in the management of HS as ustekinumab, a monoclonal antibody against IL-23 and IL-12, has demonstrated some efficacy for HS management⁷⁰.

IL-1 β is another pro-inflammatory cytokine elevated in lesional HS tissue⁶³. This cytokine is well known as a pyrogen and leukocyte-activating factor, among numerous other functions. A controlled clinical trial by Tzanetakou *et al.* determined that HS disease activity and exacerbations were attenuated with anakinra therapy. Anakinra is an antagonist of the IL-1 receptor, making the IL-1 pathway a reasonable target to pursue for disease management. Additionally, during the course of treatment with anakinra, the treatment group also exhibited decreased levels of other pro-inflammatory markers such as IL-6, TNF, and IFN- γ compared to controls, further supporting the role of the IL-1 pathway in HS pathogenesis⁷¹.

IL-6 is another pro-inflammatory molecule of interest. This cytokine is elevated in inflammatory diseases such as rheumatoid arthritis, CD, and HS. Levels of IL-6 were significantly elevated in lesional HS tissue compared to controls in a recent study by Xu *et al.*⁷². Interestingly, increased levels of IL-6 and C-reactive protein (CRP) were found to confer a poor response to infliximab treatment, making these markers reasonable adjunctive assessments in determining appropriate management⁷³. Further studies are needed to fully elucidate the role of IL-6 and methods to appropriately manage patients using this biochemical pathway.

Increased levels of chemotactic agents such as B-lymphocyte chemoattractant (BLC), CCL3, CCL5, and IL-16 have also been observed with HS^{63,74}. These cytokines similarly play a role in inflammation, particularly the acute-phase reaction⁶⁰. Interestingly, markers such as IL-2, IL-4, IL-5, and IFN- γ were found to be extremely low in perilesional HS skin⁶³.

TNF- α is secreted by both innate and adaptive immune cells and has been implicated in the disease process of many other inflammatory conditions, such as psoriasis and inflammatory bowel disease. These findings have been instrumental in the development of biologic medications and led to the first approved biologic medication for HS, adalimumab⁷⁵. TNF- α has been shown to be elevated in HS through numerous studies, indicating important involvement in the disease pathogenesis, and as an effective target for management^{64,74}.

Of note was the finding that levels of IL-1 β , TNF- α , and IL-10 correlated with increased severity of HS, further supporting these markers as suitable targets for therapy^{63,65,74}. Following this work, Hotz *et al.* observed increased levels of CD4⁺ T cells in patients

with HS and increased levels of IL-17 and IFN- γ from the aforementioned T cells⁵⁹. Another study observed cytokine concentrations in purulent drainage obtained from HS lesions and found that, overall, pro-inflammatory cytokines such as TNF- α , IL-1 β , IL-1 α , and IL-17 were increased in addition to elevations in anti-inflammatory cytokines IL-10 and IL-1ra, although each patient exhibited a unique cytokine profile. This multifaceted study also provided evidence that peripheral blood monocytes in HS patients produced fewer cytokines and were less active in responding to stimulation than were controls, indicating systemic involvement in the disease⁶⁶.

Antimicrobial peptides (AMPs), such as β -defensin (BD) 1, BD2, BD3, and other S100 proteins, such as psoriasin and calgranulins A and B, are believed to play a role in the pathogenesis of HS. AMPs are natural defense molecules constitutively expressed by keratinocytes, although irritants and other inflammatory stimulators can modify their expression. Tissue samples from six HS patients exhibited overexpression of AMPs compared to skin from healthy controls⁷⁶. Interestingly, a similar study of seven patients evaluated AMPs and cytokines within HS lesions and found a relative decrease in all analyzed AMPs. It was thought that the decrease in AMPs contributed to the susceptibility to secondary infections. This study also provided evidence that a deficiency of IL-22 and IL-20 may be responsible for decreased AMP levels, although further studies are needed on this topic⁷⁷.

From a different molecular perspective, microRNAs (miRNAs) are short, non-coding nucleotide chains involved in gene regulation. miRNAs are thought to regulate inflammatory markers in many chronic inflammatory diseases, such as psoriasis. In 2016, Hessem *et al.* observed that the miRNA modulators Drosha and DGRC8 were significantly downregulated in perilesional HS tissue, although no change was observed in these markers in lesional tissue⁷⁸. Following this work, Hessem *et al.* evaluated levels of specific miRNA molecules. Interestingly, significant overexpression of several miRNAs was observed in lesional compared to healthy control skin, including miRNA-31 and miRNA-125b. Of note, miRNA-31 is thought to be involved in regulating skin inflammation, and miRNA-125b is proposed as an important regulator of keratinocyte proliferation and TNF- α production⁷⁹. Although further studies are needed to fully assess the dysregulation of miRNA in HS, these findings contributed to the understanding of the HS disease process at the molecular level.

This information, which will surely be supplemented by future studies, has provided the basis of knowledge for understanding HS as an inflammatory disease and supported the use of biologics in its management.

Bacterial infection and biofilms

The normal bacterial flora count of the skin is approximately 1 trillion microorganisms existing in a symbiotic state with the human body. The skin hosts a variety of microbiomes, with each body part creating a specialized topographic niche for different microorganisms. Most exist in harmony with the body, although imbalances have been observed in disease processes⁸⁰. In HS, bacterial colonization develops, causing suppurating lesions, although the exact

role of microorganisms in disease pathogenesis is unknown. The immune response to the bacteria is likely abnormal, resulting in difficult-to-treat lesions.

Most HS lesions are poly-microbial in nature. The most frequently cultured bacteria from HS lesions are Gram-positive cocci and rods, such as coagulase-negative *Staphylococci* and *Corynebacterium*, as well as various subspecies of anaerobic bacteria⁸¹. One study of recalcitrant HS observed that the most commonly cultured organisms were *Corynebacterium* species (14.0%), *Staphylococcus epidermidis* (13.1%), and *Staphylococcus aureus* (10.4%)⁸². Interestingly, Jahns *et al.* evaluated 27 samples of HS lesional tissue and did not find *S. aureus* in any of the assessed samples. Of note, this was a retrospective analysis of fixed tissue using immunofluorescent labeling of samples that were not controlled for lesional depth. The absence of *S. aureus* was thought to be due to the anaerobic nature within deep HS lesions, contributing to the understanding that the identification of bacterial species is likely lesional depth dependent⁸³. It is likely that sample depth and methods of organismal assessment played a role in this finding. Guet-Revillet carried out a prospective study using a series of bacterial cultures from 102 HS lesions and determined that *S. lugdunensis*, a normal aerobic member of the skin flora, was present in 58% of the samples, making it one of the most common pathogens observed⁸⁴. The pathogens most commonly implicated in HS inflammatory lesions are benign on unaffected skin. This indicates a structural or immunologic abnormality that allows for bacterial overgrowth in HS patients, although future studies are needed to validate this hypothesis. There is still much to be learned about the microbiome and its role in HS.

Of particular interest is the complication of bacterial biofilms in HS lesions. Biofilms are observed in a variety of diseases and are associated with classic findings of chronic, non-healing inflammatory lesions with episodic acute-on-chronic flares. Often responsive at first, then resistant to antibiotic treatments, biofilm-associated lesions cause a great deal of difficulty in management. Bacterial metabolic adaptations often lower the efficacy of antimicrobial agents, making the lesions more difficult to treat⁸⁵. Biofilm development also results in a physical barrier, further contributing to decreased antibiotic efficacy. The three strains of bacteria most commonly implicated in biofilm disorders are *Pseudomonas aeruginosa*, *Enterococcus faecalis*, and *S. aureus*⁸⁶.

A recent study evaluated perilesional biopsies of 42 patients with chronic HS and found that 67% of the samples showed evidence of biofilms. Larger biofilms were associated with more extensive disease⁸⁵. Interestingly, another study evaluated acute HS lesions in 10 patients and found no evidence of biofilms⁸⁷. Although the sample size was small, this finding supports the current understanding that biofilms develop in chronic lesions. The discovery of biofilms in HS has improved the understanding of the disease process and will lead to many new directions in treatment options targeting this aspect of pathology^{85,88}. Methods of managing chronic wounds associated with biofilms are discussed below.

Classification systems

A variety of classification systems have been proposed to assess disease severity, although, recently, many methods have been developed in an attempt to capture treatment efficacy.

Hurley staging was one of the first techniques to categorize HS severity based on lesion type and proximity of neighboring lesions^{1,89}. Of clinical utility, a positive correlation of CRP levels was associated with more advanced Hurley staging⁹⁰. The Sartorius system incorporates lesion quantity and location, distance between lesions, and presence of unaffected skin in clinical staging⁵. The Physician Global Assessment (PGA) scale details six stages of disease process based on clinical criteria, with stage-specific guidelines for management and follow-up⁴.

More recently, the HS Clinical Response (HiSCR) was formulated to evaluate HS stability and assess clinical improvement. The HiSCR system first determines the patient's baseline number of abscesses and inflammatory nodules (AN count). HiSCR is a clinically determined endpoint of the disease; achievement of HiSCR50 occurs when a 50% reduction in total AN count is observed, with no increase in abscesses or draining fistulas compared to baseline⁹¹. The ability to assess the transient inflammatory components of HS is a strength of this assessment technique. Overall, although clinical staging has been helpful in the management of HS, scoring techniques often underestimate disease severity compared to other modalities, such as ultrasound⁹².

The underestimation of severity through clinical diagnosis may lead to less desirable outcomes in management. Wortsman *et al.* reported a surprising 82% modification in management approach, from medical to surgical, owing to anatomic details observed on ultrasound that were missed on physical examination⁹². The Sonographic Scoring of HS (SOS-HS) technique, developed by Wortsman *et al.*, is a standardized method of HS severity assessment using ultrasound techniques to examine HS lesions⁹²⁻⁹⁴. The use of ultrasonography in HS staging may be a valuable tool to stage HS and guide management.

Overall, a consensus of diagnostic criteria and treatment recommendations is needed to improve and streamline HS management⁴.

Management of hidradenitis suppurativa

Treatment for HS is guided by disease severity and symptomatology. While the medical, surgical, and laser management sections are separated for ease of discussion, these treatment options are not exclusive but rather exist on a continuum and are often combined to optimize treatment response. Additionally, it is important to address and properly treat underlying medical conditions to comprehensively manage patients. To date, there is no widely accepted, evidence-based treatment algorithm, although evidence-based treatment ladders have been suggested. The Henry Ford Health System in Detroit, MI, proposed an algorithm of HS management based on the treatment of more than 1,000 patients in a dedicated follicular disorders clinic (see [Figure 1](#)).

Henry Ford Hospital HS Treatment Algorithm




Figure 1. Henry Ford Hospital hidradenitis suppurativa (HS) treatment algorithm. This treatment algorithm is used in the Henry Ford Dermatology Clinic, which provides care to more than 1,000 patients with HS. The algorithm is based on a combination of evidence-based research and provider experience. BID, *bis in die*; I/L, intralesional; IV, intravenously; Nd:YAG, neodymium-doped yttrium aluminum garnet; QD, *quaque die*.

Medical management

Medical treatment optimizes a combination of agents including keratolytics, such as benzoyl peroxide or resorcinol, topical antibiotics, systemic antibiotics, hormonal modulators, systemic retinoids, intralesional corticosteroids, and, more recently, biologics and immunomodulators. The goal of medical management is to decrease disease burden and symptoms with the intent of reaching a state of remission.

Gulliver *et al.* used the European Dermatology Forum guidelines to create a treatment algorithm. This article recommended that a dermatologist well versed in HS should act as the primary coordinator of care and, initially, lifestyle modifications should always be offered. Treatment for HS begins with topical or oral antibiotics, such as clindamycin and oral tetracycline, respectively, followed by the use of rifampicin if there is no improvement. Next, biologic therapy is offered, which should be continued if the patient responds. If the response is inadequate or the patient cannot take biologics, transition to second- or third-line options is reasonable,

including surgical or laser approaches when options have been exhausted, as discussed below. The treatment regimen of advanced HS is currently in a fluid state, although research and evidence-based medicine is guiding the way towards a consensus⁹⁵.

Antibiotic treatments for HS begin as broad-spectrum regimens. Bettoli *et al.* suggested that, to improve outcomes, a multidisciplinary team approach as well as antimicrobial stewardship should be implemented to prevent long-term sequelae such as resistance, relapses, and over- or under-treatment of disease⁹⁶. Despite our best efforts, unfortunately antimicrobial resistance in HS has been reported⁹⁷.

When topical medications and oral antibiotics fail, or the disease has progressed, biologic medications can be recommended. Adalimumab, a TNF- α inhibitor, has the most evidence supporting its use. Two open-label, phase II, randomized controlled trials (RCTs) determined that weekly dosing of adalimumab statistically improved clinical response when compared to placebo controls^{98,99}.

Following these studies, two phase III trials, PIONEER I and II, described statistically improved clinical response in the adalimumab treatment group compared to placebo after 12 weeks. Specifically, 41.8% of the treated group reached HiSCR compared to 26.0% of the placebo group in PIONEER I ($p = 0.003$) and 58.9% versus 27.6% in PIONEER II ($p < 0.001$), respectively. PIONEER II also noted a statistically significant improvement in Sartorius score, from a mean of 81.4 before treatment to 52.5 at week 12 ($p < 0.001$)⁷⁵.

Second-line treatments are reasonable options in non-responders. These include infliximab (another TNF- α inhibitor) and anti-androgen therapy. Other methods of management, although fewer data exist to support their efficacy, include metformin, IL-1 receptor antagonists such as anakinra, anti-IL-17 agents, and IL-12/IL-23 pathway inhibitors such as ustekinumab.

Infliximab and etanercept have been used in the management of HS. Infliximab was one of the first TNF- α inhibitors evaluated for HS. Previous studies indicated success with infliximab treatments^{100,101}. In an eight-week, phase II study of 20 patients with moderate-to-severe HS treated with infliximab, significant improvement in pain, clinical disease severity, and quality of life were reported compared to controls¹⁰². Subsequently, Moriarty *et al.* optimized dosing regimens to every four weeks⁹⁹. Although support for the use of infliximab is strong, adalimumab offers ease of administration compared to infliximab¹⁰³. However, in the authors' experience, infliximab is more efficacious in refractory patients, despite not having FDA approval for this indication.

Etanercept is another TNF- α inhibitor of interest in the management of HS. Although initial studies were promising, subsequent studies failed to demonstrate efficacy^{104,105}.

Because of the involvement of the IL-12/Th1 and IL-23/Th17 pathways in the pathogenesis of HS, ustekinumab, a human monoclonal antibody that targets IL-12 and IL-23, was proposed as a potential modulator of HS. The first open-label study used 45 or 90 mg of ustekinumab at 0, 4, 16, and 28 weeks, which resulted in improved Sartorius scoring in 82% of 17 total patients⁷⁰.

Anakinra is an IL-1 receptor antagonist that has been implicated in the treatment of HS because of the noted elevated levels of this inflammatory cytokine and is also used in the management of AIDs owing to the role of IL-1 as a pro-inflammatory agent in this spectrum of diseases as well¹⁰⁶. Two studies have reported the efficacy of anakinra for HS; the first was an open-label study, in which five patients given 100 mg of subcutaneous anakinra showed improvement based on the modified Sartorius scoring system after 8 weeks¹⁰⁷. The second study supported these findings in Hurley stage II and III patients treated with anakinra for 12 weeks. It was found that disease activity and IFN- γ levels significantly decreased compared to in controls^{71,107}. These studies provided evidence to support continued assessments of anakinra as a plausible future treatment option.

Another promising treatment for HS is ertapenem. In a pilot study evaluating the use of ertapenem in patients with severe HS, a six-week course of 1 g of intravenous (IV) ertapenem daily followed by a consolidation treatment resulted in improved Sartorius scores. Further improvement was noted during the consolidation treatments. Patients who were not able to or did not complete the treatment stopped improving and some returned to their baseline severe disease¹⁰⁸.

Of interest in the management of HS is the use of metformin. In a small clinical study, 25 patients with refractory HS were initiated on metformin for a period of 24 weeks. Following the course, there was a significant improvement in Sartorius scores. This study seemed to strengthen the association among metabolic syndrome, disease severity, and perhaps hormonal imbalances in HS, as metformin also has anti-androgen properties¹⁰⁹. Although these initial findings were promising, subsequent studies are needed¹¹⁰. It is important to always recommend lifestyle modifications in treatment plans, as metabolic syndrome increases the risk for many other medical complications.

Colchicine, an anti-inflammatory medication, was previously discredited in having a role in HS management¹¹¹. However, a 2017 study by Armyra *et al.* indicated that colchicine might provide some clinical benefit in combination with tetracycline. This prospective series study treated all 20 patients with 100 mg minocycline daily in combination with 0.5 mg colchicine daily for 3 months. Using Hurley and Dermatology Life Quality Index (DLQI) scoring techniques, significant improvement in HS symptoms was observed¹¹².

Anti-androgen therapy has also been used in the treatment of HS. A small case series involving 20 women with mild- to moderate-severity HS were treated with spironolactone, an androgen receptor blocker, which showed improvements in disease activity. However, some of the patients were concurrently taking oral contraception, and five were taking minocycline¹¹³. The side effects of the medication were reported to be minimal, providing evidence to support further studies on the efficacy of spironolactone. Again, comorbid disease states may be a confounding factor, and lifestyle modifications for overall health are key to appropriately managing HS patients.

Biofilms pose a difficult challenge in HS management. For successful treatment, it is necessary to break down the biofilm. There is evidence to support the use of biofilm-penetrating gels, which consist of a pH buffer, benzalkonium chloride surfactant, as well as antimicrobial activity, in other chronic non-HS-related wounds¹¹⁴. Although this study was not specific to HS, it is implied that similar mechanisms may benefit chronic HS lesions. Inhibition of biofilm formation is another mechanism that may benefit HS patients. In the Lubbock chronic wound biofilm (LCWB) model, xylitol, salicylic acid, erythritol, and two novel Sanguitec gels, combined in semi-solid wound dressing formulations, inhibited biofilm formation from *P. aeruginosa*, *E. faecalis*, and *S. aureus* in the laboratory setting⁸⁶. Future directions in HS research must include HS

disease-specific biofilm management techniques to improve wound care.

The treatment of disease through intralesional corticosteroids is a unique method of symptomatic management, but, previously, evidence was limited. Intralesional triamcinolone in 10 patients resulted in both physician- and patient-reported improvement. Significant reductions in physician-assessed levels of erythema, edema, suppuration, and size were noted on days 1 and 2 following injections, while patient-reported pain scores were also significantly improved. This study provided evidence to support intralesional corticosteroid injections, although it was limited by the small sample size and lack of control group¹¹⁵. Additionally, the natural history of HS lesions with progression towards reduced inflammation, pain, and drainage complicates the interpretation of these results.

Lifestyle modifications are a major form of management that should be addressed and recommended to all patients. In particular, it is known that cigarette smoking impedes healing. In a retrospective cohort study, non-smokers were significantly more likely to exhibit improvements following first-line treatments compared to smoking counterparts¹¹⁶. In addition to smoking cessation, weight loss of more than 15% is associated with a significant improvement in disease severity^{8,117}. It is beneficial to consider lifestyle modifications in the management of all patients with HS, along with routine treatments.

Surgical and laser management

When medical management is ineffective, surgery is often the next step for HS treatment. Surgical management generally involves excision of the lesional material with or without the removal of associated scar tissue. There are both localized and extensive surgical interventions. Although there is no consensus on the best approach, procedures are carried out based on disease severity and location, with the overall goal of removing lesional tissue and sparing healthy skin to optimize outcomes.

Many approaches exist to manage HS, including local destruction, incision and drainage (I&D), standard unroofing, and wide excision techniques¹¹⁸. Local destruction is used to ablate HS lesions and may be carried out with electrosurgery, cryotherapy, or laser removal. I&D may be used for decompression in acute episodes of unbearable pain. However, I&D does not assist in the long-term resolution of disease, as the inflamed tissue remains and infection is almost certain to recur¹¹⁹. Unroofing techniques are effective for both small and large lesional units and are carried out by opening the surface of all connected abscesses and tracts within an HS lesion. The contents are removed by curettage, often leaving the site open to heal by secondary intention¹²⁰. Unroofing techniques are preferred for Hurley stage I/II, whereas skin-tissue-saving excision with electrosurgical peeling (STEEP) is preferred for Hurley stage II/III. STEEP similarly removes diseased, fibrotic tissue via electrosurgical loop while sparing healthy skin to decrease sequelae following the surgical procedure^{121,122}. Lesions that cannot be unroofed may be excised, which includes the removal of the entire diseased area up to the margins of normal-appearing subcutaneous tissue¹¹⁸.

The best surgical approach for long-term outcomes is controversial and is dependent on the patient's disease severity and location of the lesions. A recent systematic review and meta-analysis assessed for recurrence rates with varying methods of surgical management. The lowest rates of recurrence occurred following wide excision therapy when compared to local excision and deroofting procedures. This study also indicated that recurrence rates were lowest with skin grafts and skin flaps compared to primary closure, although this was limited by retrospective analysis and lack of randomization of closures¹²³. Wide excision followed by secondary intention healing was also shown to be functional and aesthetically acceptable to patients¹²⁴. Bias may exist in the discrepancy between recurrence rates and type of closure owing to the fact that primary closure is possible only with smaller wound sizes compared to larger excisions that simply cannot be closed by primary intention. Although this has not been formally assessed, the size of the wound may play a role.

The use of lasers in HS management has gained recent popularity. The 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser appears to be an effective, novel modality in HS management. After a series of treatments, two trials reported decreases in HS-associated inflammation, scarring, and fibrosis, indicating successful, selective photothermolysis to manage the disease^{125,126}. It is best used in recalcitrant Hurley stage I and II patients.

Another type of laser used in the treatment of HS is the carbon dioxide (CO₂) laser, which is used to excise HS lesions and ablate pathologic tissues. CO₂ laser has been used since the late 1980s for HS, although it is now increasing in popularity. Laser excision followed by marsupialization has been shown to be effective for the management of persistent or late-stage cases of HS, with overall patient satisfaction in post-operative quality of life and pain measures^{127,128}. Additionally, a retrospective study (n = 58) of CO₂ laser evaporation techniques reported a 29% recurrence rate of disease within 12.2 months of the procedure (noted around the borders of treated regions), while 95% of patients reported some or great improvement in disease status¹²⁹. A reported complication of CO₂ excision is scar contracture, restricted range of motion, and delayed wound healing. Nicholson *et al.* determined that fractional CO₂ therapy could be a helpful adjunct in these cases¹³⁰. For further reading, see 131–134.

Psychosocial impact

HS can be a debilitating disease, physically and emotionally, with increased prevalence of depression and psychiatric disease noted in this patient population. Onderdijk *et al.* evaluated patient-reported levels of depression, as determined through the Major Depression Inventory (MDI) questionnaire, which indicated higher scores for patients with HS compared to controls. However, clinically defined depression was not statistically more frequent. DLQI scores were significantly higher in patients with HS, indicating greater daily impact of disease³⁷. A more recent cross-sectional study utilized a database of over 4 million patients, 3,207 with HS, and found a significant association between depression and anxiety³⁶. Most recently, Kouris *et al.* noted a significant association between HS and depression, anxiety, and social isolation, as well as lower levels of self-

esteem, compared to controls¹³⁵. These studies reinforced the need for psychiatric evaluations as part of routine care for HS patients.

Due to the sensitive location of HS lesions, sexual health is often a concern for patients and their partners. A survey-based multicenter cross-sectional study of 916 HS patients reported decreased quality of life and overall sexual health as assessed by scoring techniques such as Female Sexual Function Index, International Index of Erectile Function, and DLQI³. This was one of the first large-scale assessments published on the matter. In the authors' experience, coordination with psychiatrists, psychologists, and sexual health therapists experienced in the impacts of chronic disease and chronic pain can be a valuable resource in the multidisciplinary approach to manage HS.

Social isolation and loneliness are detrimental to overall health. In a review of over 3,000 individuals, Holt-Lundstat *et al.* found an increased risk of mortality in subjects who reported feelings of loneliness and social isolation. Mortality risk was comparable to well-established risk factors, such as obesity. Subjects reporting loneliness saw a 26% increased risk of mortality, while those reporting social isolation saw a 29% increased risk of mortality¹³⁶. To combat the impacts of social isolation and loneliness, support groups can be a useful resource for both patients and providers.

There are a variety of support groups dedicated to HS, the majority of which are social media based, and a few in-person support groups. Regardless of the format, support groups offer patients the ability to interact with others facing similar circumstances and provide a sense of validation that only others with HS can provide. As with other chronic diseases, the impacts of HS are felt by caregivers, spouses, partners, family members, and friends. Participation in support groups should be considered not only for the patient but also for the caregiver.

In the author's experience, a support group that involves medical providers hosts a successful and productive format. Those with HS have often had unpleasant experiences in medicine, having suffered through mismanagement of their care and a delay in diagnosis¹⁰.

Provider involvement can ensure that accurate information about HS is disseminated and discussed. Patients can provide feedback on treatments and also make their own suggestions for new treatment options. Additionally, a provider- and patient-driven format provides an avenue to rebuild trust and the opportunity to gain insight into disease impacts through an informal setting without clinical time constraints.

Future directions

Great strides in the understanding of HS have been achieved in recent years. However, additional studies are needed to improve treatment options and patient outcomes moving forward. Future directions include increasing the awareness of HS in all fields of medicine to improve diagnoses and management, as well as continued treatment exploration, using updated knowledge on the pathogenesis of disease as the framework for future studies. With these collaborative goals in mind, multidisciplinary teams will continue to strive for success in overcoming this distressing disease.

Author contributions

Mallory Smith and Cynthia Nicholson drafted and wrote the article. Angela Miller contributed expertise for the "Psychosocial impact" section, and Iltefat Hamzavi contributed expertise on disease management. All authors were involved in the manuscript revisions and agreed on the final submission.

Competing interests

Iltefat Hamzavi is the current president of the Hidradenitis Suppurativa Foundation (non-funded) and was an investigator for AbbVie. Angela Miller has served on an advisory board and as a consultant for AbbVie and is an employee of the Hidradenitis Suppurativa Foundation. Cynthia Nicholson and Mallory Smith declare that they do not have any competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Gill L, Williams M, Hamzavi I: **Update on hidradenitis suppurativa: connecting the tracts.** *F1000Prime Rep.* 2014; **6**: 112. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Janse IC, Deckers IE, van der Maten AD, *et al.*: **Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study.** *Br J Dermatol.* 2017; **176**(4): 1042–7. [PubMed Abstract](#) | [Publisher Full Text](#)
- Alavi A, Anooshirvani N, Kim WB, *et al.*: **Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study.** *Am J Clin Dermatol.* 2015; **16**(1): 61–5. [PubMed Abstract](#) | [Publisher Full Text](#)
- Zouboulis CC, Del Marmol V, Mrowietz U, *et al.*: **Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation.** *Dermatology.* 2015; **231**(2): 184–90. [PubMed Abstract](#) | [Publisher Full Text](#)
- Alikhan A, Lynch PJ, Eisen DB: **Hidradenitis suppurativa: a comprehensive review.** *J Am Acad Dermatol.* 2009; **60**(4): 539–61; quiz 562–3. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Miller IM, McAndrew RJ, Hamzavi I: **Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa.** *Dermatol Clin.* 2016; **34**(1): 7–16. [PubMed Abstract](#) | [Publisher Full Text](#)
- Revuz J: **Hidradenitis suppurativa.** *J Eur Acad Dermatol Venereol.* 2009; **23**(9): 985–98. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kromann CB, Ibler KS, Kristiansen VB, *et al.*: **The influence of body weight on the prevalence and severity of hidradenitis suppurativa.** *Acta Derm Venereol.* 2014; **94**(5): 553–7. [PubMed Abstract](#) | [Publisher Full Text](#)
- Reeder VJ, Mahan MG, Hamzavi IH: **Ethnicity and hidradenitis suppurativa.**



- J Invest Dermatol.* 2014; **134**(11): 2842–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Saunte DM, Boer J, Stratigos A, *et al.*: **Diagnostic delay in hidradenitis suppurativa is a global problem.** *Br J Dermatol.* 2015; **173**(6): 1546–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 11. Jemec GB, Heidenheim M, Nielsen NH: **The prevalence of hidradenitis suppurativa and its potential precursor lesions.** *J Am Acad Dermatol.* 1996; **35**(2 Pt 1): 191–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Revuz JE, Canoui-Poitrine F, Wolkenstein P, *et al.*: **Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.** *J Am Acad Dermatol.* 2008; **59**(4): 596–601.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Cosmatos I, Matcho A, Weinstein R, *et al.*: **Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States.** *J Am Acad Dermatol.* 2013; **68**(3): 412–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Shahi V, Alikhan A, Vazquez BG, *et al.*: **Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County, Minnesota.** *Dermatology.* 2014; **229**(2): 154–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Vinding GR, Miller IM, Zarchi K, *et al.*: **The prevalence of inverse recurrent suppurative: a population-based study of possible hidradenitis suppurativa.** *Br J Dermatol.* 2014; **170**(4): 884–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Dufour DN, Bryld LE, Jemec GB: **Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa.** *Dermatology.* 2010; **220**(4): 323–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Danby FW: **Diet in the prevention of hidradenitis suppurativa (acne inversa).** *J Am Acad Dermatol.* 2015; **73**(5 Suppl 1): S52–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Cannistrà C, Finocchi V, Trivisonno A, *et al.*: **New perspectives in the treatment of hidradenitis suppurativa: surgery and brewer's yeast-exclusion diet.** *Surgery.* 2013; **154**(5): 1126–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. König A, Lehmann C, Rompel R, *et al.*: **Cigarette smoking as a triggering factor of hidradenitis suppurativa.** *Dermatology.* 1999; **198**(3): 261–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. **F** Miller IM, Rytgaard H, Mogensen UB, *et al.*: **Body composition and basal metabolic rate in Hidradenitis Suppurativa: a Danish population-based and hospital-based cross-sectional study.** *J Eur Acad Dermatol Venereol.* 2016; **30**(6): 980–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 21. Shlyankevich J, Chen AJ, Kim GE, *et al.*: **Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.** *J Am Acad Dermatol.* 2014; **71**(6): 1144–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. **F** Gold DA, Reeder VJ, Mahan MG, *et al.*: **The prevalence of metabolic syndrome in patients with hidradenitis suppurativa.** *J Am Acad Dermatol.* 2014; **70**(4): 699–703.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 23. Miller IM, Ellervik C, Vinding GR, *et al.*: **Association of metabolic syndrome and hidradenitis suppurativa.** *JAMA Dermatol.* 2014; **150**(12): 1273–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. **F** González-López MA, Hernández JL, Lacalle M, *et al.*: **Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS).** *J Am Acad Dermatol.* 2016; **75**(2): 329–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 25. Matusiak Ł, Szczech J, Bieniek A, *et al.*: **Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.** *J Am Acad Dermatol.* 2017; **76**(4): 670–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. **F** Egeberg A, Gislason GH, Hansen PR: **Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa.** *JAMA Dermatol.* 2016; **152**(4): 429–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 27. Kohorst JJ, Kimball AB, Davis MD: **Systemic associations of hidradenitis suppurativa.** *J Am Acad Dermatol.* 2015; **73**(5 Suppl 1): S27–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. van der Zee HH, van der Woude CJ, Florencia EF, *et al.*: **Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study.** *Br J Dermatol.* 2010; **162**(1): 195–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. **F** Egeberg A, Jemec GBE, Kimball AB, *et al.*: **Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa.** *J Invest Dermatol.* 2017; **137**(5): 1060–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 30. **F** Deckers IE, Benhadou F, Koldijk MJ, *et al.*: **Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study.** *J Am Acad Dermatol.* 2017; **76**(1): 49–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 31. **F** Yadav S, Singh S, Edakkanambeth Varayil J, *et al.*: **Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota.** *Clin Gastroenterol Hepatol.* 2016; **14**(1): 65–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 32. **F** Fimmel S, Zouboulis CC: **Comorbidities of hidradenitis suppurativa (acne inversa).** *Dermatoendocrinol.* 2010; **2**(1): 9–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 33. Herschel S, Laske J, Stein A: **Squamous cell carcinoma arising in hidradenitis suppurativa.** *J Dtsch Dermatol Ges.* 2014; **12**(5): 417–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Pena ZG, Sivamani RK, Konia TH, *et al.*: **Squamous cell carcinoma in the setting of chronic hidradenitis suppurativa: report of a patient and update of the literature.** *Dermatol Online J.* 2015; **21**(4): pii: 13030/qt9q707dp.
[PubMed Abstract](#)
 35. Lavogiez C, Delaporte E, Darras-Vercambre S, *et al.*: **Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa.** *Dermatology.* 2010; **220**(2): 147–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Shavit E, Dreijer J, Freud T, *et al.*: **Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa.** *J Eur Acad Dermatol Venereol.* 2015; **29**(2): 371–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Onderdijk AJ, van der Zee HH, Esmann S, *et al.*: **Depression in patients with hidradenitis suppurativa.** *J Eur Acad Dermatol Venereol.* 2013; **27**(4): 473–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Deckers IE, Jansse IC, van der Zee HH, *et al.*: **Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study.** *J Am Acad Dermatol.* 2016; **75**(4): 755–759.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Revuz JE, Jemec GB: **Diagnosing Hidradenitis Suppurativa.** *Dermatol Clin.* 2016; **34**(1): 1–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Moriarty B, Pink A, Creamer D, *et al.*: **Hidradenitis suppurativa fulminans: a clinically distinct phenotype?** *Br J Dermatol.* 2014; **171**(6): 1576–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Frew JW, Vekic DA, Woods J, *et al.*: **Phenotypic heterogeneity implies heterogeneous pathogenic pathways in hidradenitis suppurativa.** *Exp Dermatol.* 2015; **24**(5): 338–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. **F** Xu H, Xiao X, Hui Y, *et al.*: **Phenotype of 53 Chinese individuals with nicastrin gene mutations in association with familial hidradenitis suppurativa (acne inversa).** *Br J Dermatol.* 2016; **174**(4): 927–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 43. **F** Canoui-Poitrine F, Le Thuaut A, Revuz JE, *et al.*: **Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study.** *J Invest Dermatol.* 2013; **133**(6): 1506–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 44. **F** Strowig T, Henao-Mejia J, Elinav E, *et al.*: **Inflammasomes in health and disease.** *Nature.* 2012; **481**(7381): 278–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 45. Marzano AV, Trevisan V, Gattorno M, *et al.*: **Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the *PSTPIP1* gene.** *JAMA Dermatol.* 2013; **149**(6): 762–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. **F** Braun-Falco M, Kovnerysty O, Lohse P, *et al.*: **Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome.** *J Am Acad Dermatol.* 2012; **66**(3): 409–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 47. **F** Wang B, Yang W, Wen W, *et al.*: **Gamma-secretase gene mutations in familial acne inversa.** *Science.* 2010; **330**(6007): 1065.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 48. Prens E, Deckers I: **Pathophysiology of hidradenitis suppurativa: An update.** *J Am Acad Dermatol.* 2015; **73**(5 Suppl 1): S8–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Nomura Y, Nomura T, Suzuki S, *et al.*: **A novel *NCSTN* mutation alone may be insufficient for the development of familial hidradenitis suppurativa.** *J Dermatol Sci.* 2014; **74**(2): 180–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. **F** Xiao X, He Y, Li C, *et al.*: **Nicastrin mutations in familial acne inversa impact keratinocyte proliferation and differentiation through the Notch and phosphoinositide 3-kinase/AKT signalling pathways.** *Br J Dermatol.* 2016; **174**(3): 522–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 51. **F** Duchatelet S, Miskinyte S, Join-Lambert O, *et al.*: **First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome.** *Br J Dermatol.* 2015; **173**(2): 610–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. **F** Deckers IE, van der Zee HH, Boer J, *et al.*: **Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement.** *J Am Acad Dermatol.* 2015; **72**(3): 485–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

53. Vekic DA, Frew JW, Woods J, *et al.*: **Adopting the orphan: The importance of recognising hidradenitis suppurativa as a systemic auto-inflammatory disease.** *Australas J Dermatol.* 2016; **57**(1): 69–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Kurayev A, Ashkar H, Saraiya A, *et al.*: **Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment.** *J Drugs Dermatol.* 2016; **15**(8): 1017–22.
[PubMed Abstract](#)
55. van der Zee HH, de Ruyter L, Boer J, *et al.*: **Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions.** *Br J Dermatol.* 2012; **166**(1): 98–106.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Danby FW, Jemec GB, Marsch WCh, *et al.*: **Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support.** *Br J Dermatol.* 2013; **168**(5): 1034–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
57. Blok JL, Janse IC, Horváth B, *et al.*: **Increased expression of integrin $\alpha 6 \beta 4$ in the basement membrane zone lining the sebaceous glands in hidradenitis suppurativa.** *Acta Derm Venereol.* 2015; **95**(8): 994–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. Lima AL, Karl I, Giner T, *et al.*: **Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.** *Br J Dermatol.* 2016; **174**(3): 514–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Hotz C, Boniotti M, Guiguin A, *et al.*: **Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa.** *J Invest Dermatol.* 2016; **136**(9): 1768–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
60. Kelly G, Prens EP: **Inflammatory Mechanisms in Hidradenitis Suppurativa.** *Dermatol Clin.* 2016; **34**(1): 51–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Jemec GB: **Hidradenitis suppurativa and immune dysregulation.** *Br J Dermatol.* 2012; **166**(2): 237–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, *et al.*: **Altered innate and adaptive immune responses in patients with hidradenitis suppurativa.** *Br J Dermatol.* 2007; **156**(1): 51–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
63. van der Zee HH, de Ruyter L, van den Broecke DG, *et al.*: **Elevated levels of tumour necrosis factor (TNF)- α , interleukin (IL)-1 β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF- α and IL-1 β .** *Br J Dermatol.* 2011; **164**(6): 1292–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Mozeika E, Pilmane M, Nürnberg BM, *et al.*: **Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa.** *Acta Derm Venereol.* 2013; **93**(3): 301–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Kelly G, Hughes R, McGarry T, *et al.*: **Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.** *Br J Dermatol.* 2015; **173**(6): 1431–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Kanni T, Tzanetakou V, Savva A, *et al.*: **Compartmentalized Cytokine Responses in Hidradenitis Suppurativa.** *PLoS One.* 2015; **10**(6): e0130522.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Schlapbach C, Hänni T, Yawalkar N, *et al.*: **Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.** *J Am Acad Dermatol.* 2011; **65**(4): 790–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
68. Dréno B, Khammari A, Brocard A, *et al.*: **Hidradenitis suppurativa: the role of deficient cutaneous innate immunity.** *Arch Dermatol.* 2012; **148**(2): 182–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Speeckaert R, Lambert J, Grine L, *et al.*: **The many faces of interleukin-17 in inflammatory skin diseases.** *Br J Dermatol.* 2016; **175**(5): 892–901.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Blok JL, Li K, Brodmerkel C, *et al.*: **Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum.** *Br J Dermatol.* 2016; **174**(4): 839–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
71. Tzanetakou V, Kanni T, Giatrakou S, *et al.*: **Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.** *JAMA Dermatol.* 2016; **152**(1): 52–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
72. Xu H, Xiao X, He Y, *et al.*: **Increased serum interleukin-6 levels in patients with hidradenitis suppurativa.** *Postepy Dermatol Alergol.* 2017; **34**(1): 82–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
73. Montaudí H, Seitz-Polski B, Cornille A, *et al.*: **Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa.** *J Am Acad Dermatol.* 2017; **76**(1): 156–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
74. van der Zee HH, Laman JD, de Ruyter L, *et al.*: **Adalimumab (antitumour necrosis factor- α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an *in situ* and *ex vivo* study.** *Br J Dermatol.* 2012; **166**(2): 298–305.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
75. Kimball AB, Okun MM, Williams DA, *et al.*: **Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.** *N Engl J Med.* 2016; **375**(5): 422–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
76. Schlapbach C, Yawalkar N, Hunger RE: **Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa.** *J Am Acad Dermatol.* 2009; **61**(1): 58–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
77. Wolk K, Warsawska K, Hoeflich C, *et al.*: **Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa.** *J Immunol.* 2011; **186**(2): 1228–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
78. Hessam S, Sand M, Skrygan M, *et al.*: **Inflammation induced changes in the expression levels of components of the microRNA maturation machinery Drosha, Dicer, Drosha co-factor DGRC8 and Exportin-5 in inflammatory lesions of hidradenitis suppurativa patients.** *J Dermatol Sci.* 2016; **82**(3): 166–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
79. Hessam S, Sand M, Skrygan M, *et al.*: **Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the Inflammatory Pathway of Hidradenitis Suppurativa.** *Inflammation.* 2017; **40**(2): 464–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
80. Hannigan GD, Grice EA: **Microbial ecology of the skin in the era of metagenomics and molecular microbiology.** *Cold Spring Harb Perspect Med.* 2013; **3**(12): a015362.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Ring HC, Emtestam L: **The Microbiology of Hidradenitis Suppurativa.** *Dermatol Clin.* 2016; **34**(1): 29–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Thomas C, Rodby KA, Thomas J, *et al.*: **Recalcitrant Hidradenitis Suppurativa: An Investigation of Demographics, Surgical Management, Bacterial Isolates, Pharmacologic Intervention, and Patient-reported Health Outcomes.** *Am Surg.* 2016; **82**(4): 362–8.
[PubMed Abstract](#) | [F1000 Recommendation](#)
83. Jahns AC, Killasli H, Nosek D, *et al.*: **Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients.** *APMIS.* 2014; **122**(9): 804–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
84. Guet-Revillet H, Coignard-Biehler H, Jais JP, *et al.*: **Bacterial pathogens associated with hidradenitis suppurativa, France.** *Emerging Infect Dis.* 2014; **20**(12): 1990–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Ring HC, Bay L, Nilsson M, *et al.*: **Bacterial biofilm in chronic lesions of hidradenitis suppurativa.** *Br J Dermatol.* 2017; **176**(4): 993–1000.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
86. Dowd SE, Sun Y, Smith E, *et al.*: **Effects of biofilm treatments on the multi-species Lubbock chronic wound biofilm model.** *J Wound Care.* 2009; **18**(12): 508, 510–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Okoye GA, Vlassova N, Olowoyeye O, *et al.*: **Bacterial biofilm in acute lesions of hidradenitis suppurativa.** *Br J Dermatol.* 2017; **176**(1): 241–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
88. Stoodley P: **Evidence for a biofilm-based treatment strategy in the management of chronic hidradenitis suppurativa.** *Br J Dermatol.* 2017; **176**(4): 855–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Hurley H: **Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach.** *Dermatologic Surgery.* 1989; **133**: 1506–11
90. Hessam S, Sand M, Gambichler T, *et al.*: **Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).** *J Am Acad Dermatol.* 2015; **73**(6): 998–1005.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Kimball AB, Sobell JM, Zouboulis CC, *et al.*: **HISCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.** *J Eur Acad Dermatol Venereol.* 2016; **30**(6): 989–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Wortsman X, Moreno C, Soto R, *et al.*: **Ultrasound in-depth characterization and staging of hidradenitis suppurativa.** *Dermatol Surg.* 2013; **39**(12): 1835–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
93. Kelekis NL, Efstathopoulos E, Balanika A, *et al.*: **Ultrasound aids in diagnosis and severity assessment of hidradenitis suppurativa.** *Br J Dermatol.* 2010; **162**(6): 1400–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Wortsman X, Wortsman J: **Ultrasound Detection of Retained Hair Tracts in Hidradenitis Suppurativa.** *Dermatol Surg.* 2015; **41**(7): 867–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Gulliver W, Zouboulis CC, Prens E, *et al.*: **Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European**

- guidelines for hidradenitis suppurativa. *Rev Endocr Metab Disord*. 2016; 17(3): 343–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
96. Bettoli V, Join-Lambert O, Nassif A: **Antibiotic Treatment of Hidradenitis Suppurativa**. *Dermatol Clin*. 2016; 34(1): 81–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Fischer AH, Haskin A, Okoye GA: **Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa**. *J Am Acad Dermatol*. 2017; 76(2): 309–313.e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. **F** Kimball AB, Kerdel F, Adams D, *et al.*: **Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial**. *Ann Intern Med*. 2012; 157(12): 846–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
99. Amano M, Grant A, Kerdel FA: **A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa**. *Int J Dermatol*. 2010; 49(8): 950–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Sullivan TP, Welsh E, Kerdel FA, *et al.*: **Infliximab for hidradenitis suppurativa**. *Br J Dermatol*. 2003; 149(5): 1046–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Brunasso AM, Delfino C, Massone C: **Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?** *Br J Dermatol*. 2008; 159(3): 761–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. **F** Grant A, Gonzalez T, Montgomery MO, *et al.*: **Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial**. *J Am Acad Dermatol*. 2010; 62(2): 205–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
103. Moul DK, Korman NJ: **The cutting edge. Severe hidradenitis suppurativa treated with adalimumab**. *Arch Dermatol*. 2006; 142(9): 1110–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
104. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, *et al.*: **An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa**. *Br J Dermatol*. 2008; 158(3): 567–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Adams DR, Yankura JA, Fogelberg AC, *et al.*: **Treatment of hidradenitis suppurativa with etanercept injection**. *Arch Dermatol*. 2010; 146(5): 501–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Federici S, Martini A, Gattorno M: **The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases**. *Front Immunol*. 2013; 4: 351.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Leslie KS, Tripathi SV, Nguyen TV, *et al.*: **An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa**. *J Am Acad Dermatol*. 2014; 70(2): 243–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. **F** Join-Lambert O, Coignard-Biehler H, Jais JP, *et al.*: **Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients**. *J Antimicrob Chemother*. 2016; 71(2): 513–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
109. **F** Verdolini R, Clayton N, Smith A, *et al.*: **Metformin for the treatment of hidradenitis suppurativa: a little help along the way**. *J Eur Acad Dermatol Venereol*. 2013; 27(9): 1101–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
110. Lim ZV, Oon HH: **Management of Hidradenitis Suppurativa in Patients with Metabolic Comorbidities**. *Ann Dermatol*. 2016; 28(2): 147–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
111. van der Zee HH, Prens EP: **The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa**. *Dermatology*. 2011; 223(2): 169–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
112. **F** Armyra K, Kouris A, Markantoni V, *et al.*: **Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients**. *Int J Dermatol*. 2017; 56(3): 346–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
113. **F** Lee A, Fischer G: **A case series of 20 women with hidradenitis suppurativa treated with spironolactone**. *Australas J Dermatol*. 2015; 56(3): 192–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
114. Wolcott R: **Disrupting the biofilm matrix improves wound healing outcomes**. *J Wound Care*. 2015; 24(8): 366–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
115. **F** Riis PT, Boer J, Prens EP, *et al.*: **Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series**. *J Am Acad Dermatol*. 2016; 75(6): 1151–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
116. **F** Denny G, Anadkat MJ: **The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study**. *J Am Acad Dermatol*. 2017; 76(1): 54–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
117. Thomas CL, Gordon KD, Mortimer PS: **Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention**. *Clin Exp Dermatol*. 2014; 39(3): 315–7; quiz 317–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Danby FW, Hazen PG, Boer J: **New and traditional surgical approaches to hidradenitis suppurativa**. *J Am Acad Dermatol*. 2015; 73(5 Suppl 1): S62–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. Jemec GB: **Clinical practice. Hidradenitis suppurativa**. *N Engl J Med*. 2012; 366(2): 158–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
120. Danby FW: **Commentary: unroofing for hidradenitis suppurativa, why and how**. *J Am Acad Dermatol*. 2010; 63(3): 481.e1–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
121. **F** Blok JL, Spoo JR, Leeman FW, *et al.*: **Skin-Tissue-sparing Excision with Electrosurgical Peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II/III**. *J Eur Acad Dermatol Venereol*. 2015; 29(2): 379–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
122. Blok JL, Boersma M, Terra JB, *et al.*: **Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients**. *J Eur Acad Dermatol Venereol*. 2015; 29(8): 1590–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
123. **F** Mehdizadeh A, Hazen PG, Bechara FG, *et al.*: **Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis**. *J Am Acad Dermatol*. 2015; 73(5 Suppl 1): S70–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
124. Humphries LS, Kueberuwa E, Beederman M, *et al.*: **Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: A single-center experience**. *J Plast Reconstr Aesthet Surg*. 2016; 69(4): 554–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
125. Tierney E, Mahmoud BH, Hexsel C, *et al.*: **Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser**. *Dermatol Surg*. 2009; 35(8): 1188–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
126. **F** Xu LY, Wright DR, Mahmoud BH, *et al.*: **Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment**. *Arch Dermatol*. 2011; 147(1): 21–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
127. **F** Hazen PG, Hazen BP: **Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization**. *Dermatol Surg*. 2010; 36(2): 208–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
128. **F** Madan V, Hindle E, Hussain W, *et al.*: **Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser**. *Br J Dermatol*. 2008; 159(6): 1309–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
129. **F** Mikkelsen PR, Dufour DN, Zarchi K, *et al.*: **Recurrence rate and patient satisfaction of CO2 laser evaporation of lesions in patients with hidradenitis suppurativa: a retrospective study**. *Dermatol Surg*. 2015; 41(2): 255–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
130. Nicholson CL, Hamzavi I, Ozog DM: **Rapid healing of chronic ulcerations and improvement in range of motion after fractional carbon dioxide (CO₂) treatment after CO₂ excision of hidradenitis suppurativa axillary lesions: A case report**. *JAAD Case Rep*. 2016; 2(1): 4–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Dessinioti C, Zisimou C, Tzanetakou V, *et al.*: **Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up**. *Clin Exp Dermatol*. 2016; 41(8): 852–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
132. Join-Lambert O, Coignard H, Jais JP, *et al.*: **Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa**. *Dermatology*. 2011; 222(1): 49–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
133. van der Zee HH, Prens EP, Boer J: **Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions**. *J Am Acad Dermatol*. 2010; 63(3): 475–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
134. Paradelo S, Rodríguez-Lojo R, Fernández-Torres R, *et al.*: **Long-term efficacy of infliximab in hidradenitis suppurativa**. *J Dermatolog Treat*. 2012; 23(4): 278–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
135. **F** Kouris A, Platsidaki E, Christodoulou C, *et al.*: **Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa**. *Dermatology*. 2016; 232(6): 687–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
136. Holt-Lunstad J, Smith TB, Baker M: **Loneliness and social isolation as risk factors for mortality: a meta-analytic review**. *Perspect Psychol Sci*. 2015; 10(2): 227–37.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Referee Status:



Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious **F1000 Faculty** and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- 1 **Geoffrey David Cains** Department of Dermatology, University of New South Wales, Sydney, Australia
Competing Interests: No competing interests were disclosed.
- 1 **Christopher Sayed**^{1,2} 1 Department of Dermatology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 UNC Dermatology and Skin Cancer Center, Chapel Hill, NC, USA
Competing Interests: Christopher Sayed has held roles with Abbvie Inc. as a speaker, Advisory Board Member and co-investigator.
- 1 **Robert Micheletti** Department of Dermatology and Department of Medicine, University of Pennsylvania, Philadelphia, USA
Competing Interests: No competing interests were disclosed.